C
Carolyn J. Henry
Researcher at University of Missouri
Publications - 113
Citations - 4151
Carolyn J. Henry is an academic researcher from University of Missouri. The author has contributed to research in topics: Cancer & Hemangiosarcoma. The author has an hindex of 36, co-authored 111 publications receiving 3700 citations. Previous affiliations of Carolyn J. Henry include University of Alabama & Auburn University.
Papers
More filters
Journal ArticleDOI
Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision
Cheryl A. London,Phyllis B. Malpas,Stacey L. Wood-Follis,Joseph F. Boucher,Anthony Rusk,Mona P. Rosenberg,Carolyn J. Henry,Kathy L. Mitchener,Mary K. Klein,John G. Hintermeister,Philip J. Bergman,Guillermo Couto,Guy N. Mauldin,Gina M. Michels +13 more
TL;DR: Palladia has biological activity against canine MCTs and can be administered on a continuous schedule without need for routine planned treatment breaks, and shows that spontaneous tumors in dogs are good models to evaluate therapeutic index of targeted therapeutics in a clinical setting.
Journal ArticleDOI
Amputation and Carboplatin for Treatment of Dogs With Osteosarcoma: 48 Cases (1991 to 1993)
Philip J. Bergman,E. Gregory MacEwen,Ilene D. Kurzman,Carolyn J. Henry,A S Hammer,Deborah W. Knapp,Ann Hale,Stephen A. Kruth,Mary K. Klein,Jeffrey S. Klausner,Alan M. Norris,Dudley L. McCaw,Rodney C. Straw,Stephen J. Withrow +13 more
TL;DR: Carboplatin appears to be a well-tolerated chemotherapeutic drug that can be given safely every 21 days at a dose of 300 mg/m2 and Neutropenia was the dose-limiting toxicity in this study.
Journal ArticleDOI
Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours
Cheryl A. London,Tamra Mathie,Nicole Stingle,Craig A. Clifford,Siobhan Haney,Mary K. Klein,Linda Beaver,Kate Vickery,David M. Vail,Betsey Hershey,Susan Ettinger,Andrew Vaughan,Francisco J. Alvarez,Lorin Hillman,Mike Kiselow,Doug H. Thamm,Mary Lynn Higginbotham,Meredith Gauthier,Erika L. Krick,Brenda Phillips,Tracy Ladue,Pam Jones,Jeffery Bryan,Virginia L. Gill,Andrew Novasad,Lisa Fulton,Janet K. Carreras,C. J. McNeill,Carolyn J. Henry,Sarah Gillings +29 more
TL;DR: Preliminary evidence that toceranib exhibits CB in dogs with certain solid tumours is provided, although future prospective studies are necessary to define its true activity.
Journal ArticleDOI
A population study of neutering status as a risk factor for canine prostate cancer.
Jeffrey N. Bryan,Matthew R. Keeler,Carolyn J. Henry,Margaret E. Bryan,Allen W. Hahn,Charles W. Caldwell +5 more
TL;DR: The hypothesis was that castration is a risk factor for prostate cancer in male companion dogs, and a large population database was evaluated to evaluate risk of prostate cancer.
Journal ArticleDOI
Treatment of Canine Hemangiosarcoma: 2000 and Beyond
TL;DR: The use of multimodality therapy incorporating innovative treatment modalities may offer the best therapeutic option for dogs affected with HSA.